Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.
about
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerProstate Radiotherapy in the Era of Advanced Imaging and Precision MedicineDeoxyribonucleic acid damage-associated biomarkers of ionising radiation: current status and future relevance for radiology and radiotherapyModeling positioning uncertainties of prostate cancer external beam radiation therapy using pre-treatment data.Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer.Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.Significance of image guidance to clinical outcomes for localized prostate cancerTransitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysisCurrent state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013".Clinical management and burden of prostate cancer: a Markov Monte Carlo model.Proctitis following stereotactic body radiation therapy for prostate cancerEarly Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost.Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.Whole pelvic intensity-modulated radiotherapy for gynecological malignancies: A review of the literature.Three-dimensional conformal arc radiotherapy using a C-arm linear accelerator with a computed tomography on-rail system for prostate cancer: clinical outcomes.The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.Nomogram to predict rectal toxicity following prostate cancer radiotherapy.Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes.Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design.The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.Translational and clinical implications of the genetic landscape of prostate cancer.A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints.Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospectClassifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?Partial-Body Irradiation in Patients with Prostate Cancer Treated with IMRT Has Little Effect on the Composition of Serum Proteome.Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.Reducing rectal injury during external beam radiotherapy for prostate cancer.Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.Progress and controversies: Radiation therapy for prostate cancer.Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.Guidance on patient consultation. Current evidence for prostate-specific antigen screening in healthy men and treatment options for men with proven localised prostate cancer.Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.
P2860
Q26747782-232A21D9-E453-4290-AB6D-F4621BFAA73FQ26749961-230AB8DA-7EC0-44E9-B911-D9EB5E6E702BQ26866394-1917032F-0A11-4706-AF2C-243ABE8BC7B6Q30762124-E42C3014-F616-45D7-B10A-EE6087A8B1BEQ33461489-D30095DE-CEC0-444B-AAE4-49A6D8F2FC9CQ33668168-EAF66F2B-1CF0-4DB3-B7C2-49BBE5051527Q33924077-28689187-B31C-4C4A-A10F-FE94A387BA17Q33993238-7F8A9D91-DC9A-463F-A577-D3FB485C956CQ34500966-F3EFA574-EC5A-4D11-84EE-F75FE5FB2183Q34528219-1CA99966-AB37-4B6D-86D3-0376E17FCDC3Q34634410-F02DC8B0-472E-4C2F-A22A-B76C4C8429D1Q34748877-72A6D784-0132-4C45-973F-C5296CCC956AQ35111988-D6DF821F-EB12-48D9-8CA2-F70DE4D5DDA3Q35174871-D3A21C8F-BA57-4F71-9B4C-B5672279A74CQ35235550-469C49B2-F169-44E3-B9D9-0873CD6C034DQ35515150-5D4C5E7E-E657-44B5-812E-791415CEAF9CQ35572060-32EB40B5-08D9-4D59-B175-239CF458B34FQ36156751-B91CF7DD-D3F3-4A18-9962-B7860E7D7C20Q36259082-D8286909-BA5A-4993-BE81-3EA9879313BDQ36412497-C410771D-2697-4C8B-BFE9-B06EAB3200DFQ36672787-44A80287-FC74-4C3D-9E8A-53F16827A1F3Q37025528-32B67233-C943-45F9-981D-A71ED318CA76Q37110245-4C7561B1-1937-474D-A4E1-7942E5ED7D12Q37154093-700E257C-12FE-429E-8054-A600C9DA8592Q37213044-DD731CF7-BF30-48AF-8301-E40C4142A30DQ37270512-9DAD7B59-430D-40F5-8A3B-1E7BB88FBC67Q37386325-7410EB97-63EE-4B32-8234-4DEFDFAC453BQ37528968-279B67B6-A67E-428B-ACB7-81E9582F4C76Q37563875-72C736B2-0868-4DA5-A444-2208601EEE3AQ37566459-075AFE11-1FFF-4657-AD9B-D53716A5A672Q37580538-A66CFB31-A14A-4FE4-A377-841B09018FE5Q37713417-D3C1BEFF-EC1C-48FE-B9B4-62B58114B8C8Q38106626-42C79B9D-772A-400D-BAC6-243CD4FBACC4Q38180344-EFFCEE8D-84AE-48E3-B7BF-D18B9040186DQ38252429-466923D7-5229-4CDD-9FCB-B2E0B180E921Q38362692-03863226-BD39-4EF1-8A5C-64C787FDF43FQ38379141-5FECCFB5-3799-4C0C-BED1-00FF2FF8E9DDQ38437266-F7D81B79-4099-4C61-AFB6-8F2941232803Q38839208-2171094B-22B3-4920-8B75-83354789D6B1Q39088175-00DA3907-43FA-4ADC-801A-A025017C62F6
P2860
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Long-term survival and toxicit ...... for localized prostate cancer.
@en
Long-term survival and toxicit ...... for localized prostate cancer.
@nl
type
label
Long-term survival and toxicit ...... for localized prostate cancer.
@en
Long-term survival and toxicit ...... for localized prostate cancer.
@nl
prefLabel
Long-term survival and toxicit ...... for localized prostate cancer.
@en
Long-term survival and toxicit ...... for localized prostate cancer.
@nl
P2093
P2860
P1476
Long-term survival and toxicit ...... for localized prostate cancer.
@en
P2093
Josh Yamada
Marisa A Kollmeier
P2860
P304
P356
10.1016/J.IJROBP.2012.05.023
P407
P577
2012-07-12T00:00:00Z